Department of Anesthesiology, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.
J Clin Pharmacol. 2022 Aug;62(8):935-947. doi: 10.1002/jcph.2039. Epub 2022 Mar 29.
Dexmedetomidine has been identified as a useful adjunct to improve the effect of nerve blocks in adults; however, its effect for children has not yet been fully investigated. This meta-analysis aimed to evaluate the reliability and efficacy of dexmedetomidine as a local anesthetic adjunct for pediatric surgeries. Eligible studies were searched in Cochrane, Embase, PubMed, and CBM. RevMan 5.4 was used to assess the risk of bias of each study and perform statistical analysis. Stata 15.0 was used to evaluate the publication bias of primary outcomes. Thirteen randomized controlled trial (RCTs) involving 722 patients aged 6 months to 12 years were harvested. Statistical analysis showed that dexmedetomidine resulted in: a significantly longer duration of analgesia (standardized mean difference [SMD], 7.16; 95% confidence interval [95%CI], 4.88 to 9.43; P < .001; I = 98%); a reduction in the 1-hour pain score (mean difference [MD], -0.27; 95%CI, -0.47 to -0.06; P = .01; I = 28%); cumulative doses of rescue analgesic required of 2 doses (risk ratio [RR], 0.26; 95%CI, 0.14 to 0.49; P < .001; I = 0) or 3 doses (RR, 0.04; 95%CI, 0.01 to 0.16; P < .001; I = 4%); the frequency of emergence agitation (RR, 0.44; 95%CI, 0.22 to 0.91; P = .03; I = 0); and a reduction in the onset time of blocks (mean difference -3.56; 95%CI, -6.39 to -0.74; P = .01; I = 90%). However, the incidence of some side effects, including hypotension, bradycardia, nausea and vomiting, pruritis, urinary retention, and respiratory depression, did not significantly differ between the dexmedetomidine group and the placebo group. Therefore, dexmedetomidine is a reliable and efficient adjunct to local anesthetics in children.
右美托咪定已被确定为一种有用的辅助药物,可以提高成人神经阻滞的效果;然而,其在儿童中的效果尚未得到充分研究。本荟萃分析旨在评估右美托咪定为儿科手术提供局部麻醉辅助的可靠性和疗效。在 Cochrane、Embase、PubMed 和 CBM 中搜索符合条件的研究。使用 RevMan 5.4 评估每项研究的偏倚风险并进行统计分析。使用 Stata 15.0 评估主要结局的发表偏倚。共纳入 13 项随机对照试验(RCT),涉及 722 名 6 个月至 12 岁的患儿。统计分析显示,右美托咪定可显著延长镇痛持续时间(标准化均数差 [SMD],7.16;95%置信区间 [95%CI],4.88 至 9.43;P<0.001;I²=98%);1 小时疼痛评分降低(MD,-0.27;95%CI,-0.47 至 -0.06;P=0.01;I²=28%);2 剂(RR,0.26;95%CI,0.14 至 0.49;P<0.001;I²=0)或 3 剂(RR,0.04;95%CI,0.01 至 0.16;P<0.001;I²=4%)所需的补救性镇痛药物累积剂量;(RR,0.44;95%CI,0.22 至 0.91;P=0.03;I²=0)出现激越的频率;(RR,0.44;95%CI,0.22 至 0.91;P=0.03;I²=0)块的发作时间减少(MD,-3.56;95%CI,-6.39 至 -0.74;P=0.01;I²=90%)。然而,右美托咪定组与安慰剂组之间的一些不良反应(包括低血压、心动过缓、恶心和呕吐、瘙痒、尿潴留和呼吸抑制)的发生率无显著差异。因此,右美托咪定是儿童局部麻醉的一种可靠且有效的辅助药物。